Semisolid formulations containing dimethyl sulfoxide and α-tocopherol for the treatment of extravasation of antiblastic agents

The topical treatment with dimethyl sulfoxide (DMSO) and/or alpha-tocopherol (alpha-T) is widely used in order to prevent the local complications of extravasation of cytostatic drugs and protect patients against skin ulceration. Till now, DMSO and alpha-T have been mainly used in solution. The goal...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archives of Dermatological Research 2007-07, Vol.299 (4), p.201-207
Hauptverfasser: CASIRAGHI, Antonella, ARDOVINO, Paola, MINGHETTI, Paola, BOTTA, Cinzia, GATTINI, Arrigo, MONTANARI, Luisa
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 207
container_issue 4
container_start_page 201
container_title Archives of Dermatological Research
container_volume 299
creator CASIRAGHI, Antonella
ARDOVINO, Paola
MINGHETTI, Paola
BOTTA, Cinzia
GATTINI, Arrigo
MONTANARI, Luisa
description The topical treatment with dimethyl sulfoxide (DMSO) and/or alpha-tocopherol (alpha-T) is widely used in order to prevent the local complications of extravasation of cytostatic drugs and protect patients against skin ulceration. Till now, DMSO and alpha-T have been mainly used in solution. The goal of this study was to formulate semisolid preparations for cutaneous application differing in the hydrophilic and lipophilic properties and containing DMSO and alpha-T in combination. With respect to solutions, the use of semisolid preparations containing DMSO and alpha-T could be advantageous in patients having extravasation as DMSO and alpha-T can remain in contact with the skin over an extended period of time. As a consequence, the action of the active principles can be limited specifically on the injured skin area, reducing the cutaneous irritative effects of DMSO. The following types of semisolid formulations containing 50% m/m DMSO and 2.5% m/m alpha-T were prepared: hydrophilic ointment, o/w emulsion, hydrophilic gel and lipophilic gel. The ex vivo skin permeation of DMSO and alpha-T was evaluated by using modified Franz's diffusion cells and human stratum corneum and epidermis (SCE) as a membrane. The permeated and retained amounts of DMSO and alpha-T were determined. The oleogel preparation, the hydrophilic gel and the o/w emulsion were uniform in colour and aspect, without any evidences of phase separation over the period of the study. Hydrophilic ointments were discarded as they showed phase separation after 12 h. All formulations had a different behaviour in terms of skin permeability. In particular, hydrogel and o/w emulsion showed the best control on the drug release considering the interactions of the vehicle components with the SCE and the drugs partition between the vehicle and the SCE. The DMSO permeated amount after 24 h was 4.1 mg/cm(2) for hydrogel and 2.5 mg/cm(2) for emulsion while the permeated amount of pure DMSO after 24 h was 47.5 mg/cm(2). Therefore, aiming to reduce side effects after the topical application of the antidotes DMSO and alpha-T, these results suggested that hydrogel and o/w emulsion could be considered the most promising formulations for further clinical evaluations in managing of extravasation of anthracyclines.
doi_str_mv 10.1007/s00403-007-0746-9
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2664867189</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2664867189</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-c1a6e16d1825c241890fc63623fb9d1a8724b2eb0a58291f2f4bd35a011d49613</originalsourceid><addsrcrecordid>eNpFkE1qHDEQhUWIiQfbB8gmCEKWcko_I6mXwcRJwJBFHMiuUevHI9MtTSR1sFc5Uy7iM6XbM-Da1KP43it4CL2lcEkB1McKIICTRRJQQpLuFdpQwRkB2f16jTbABRAuO3mKLmq9h2UUCAbqDTqliisATTfo7w8_xZrH6HDIZZpH02JOFducmokppjvs4uTb7nHEdR5DfojOY5McfvpHWrZ5v_Mlj6sZt53HrXjTJp8azgH7h1bMH1OfM9eDSS0Oo6ktWmzuFqqeo5NgxuovjvsM_bz-fHv1ldx8__Lt6tMNsXyrGrHUSE-lo5ptLRNUdxCs5JLxMHSOGq2YGJgfwGw162hgQQyObw1Q6kQnKT9D7w-5-5J_z762_j7PJS0veyal0FItmQtFD5QtudbiQ78vcTLlsafQr633h9b7Va6t96vn3TF5HibvXhzHjhfgwxEw1ZoxFJNsrC-c1ppTkPw_kdiMxg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2664867189</pqid></control><display><type>article</type><title>Semisolid formulations containing dimethyl sulfoxide and α-tocopherol for the treatment of extravasation of antiblastic agents</title><source>MEDLINE</source><source>SpringerNature Complete Journals</source><creator>CASIRAGHI, Antonella ; ARDOVINO, Paola ; MINGHETTI, Paola ; BOTTA, Cinzia ; GATTINI, Arrigo ; MONTANARI, Luisa</creator><creatorcontrib>CASIRAGHI, Antonella ; ARDOVINO, Paola ; MINGHETTI, Paola ; BOTTA, Cinzia ; GATTINI, Arrigo ; MONTANARI, Luisa</creatorcontrib><description>The topical treatment with dimethyl sulfoxide (DMSO) and/or alpha-tocopherol (alpha-T) is widely used in order to prevent the local complications of extravasation of cytostatic drugs and protect patients against skin ulceration. Till now, DMSO and alpha-T have been mainly used in solution. The goal of this study was to formulate semisolid preparations for cutaneous application differing in the hydrophilic and lipophilic properties and containing DMSO and alpha-T in combination. With respect to solutions, the use of semisolid preparations containing DMSO and alpha-T could be advantageous in patients having extravasation as DMSO and alpha-T can remain in contact with the skin over an extended period of time. As a consequence, the action of the active principles can be limited specifically on the injured skin area, reducing the cutaneous irritative effects of DMSO. The following types of semisolid formulations containing 50% m/m DMSO and 2.5% m/m alpha-T were prepared: hydrophilic ointment, o/w emulsion, hydrophilic gel and lipophilic gel. The ex vivo skin permeation of DMSO and alpha-T was evaluated by using modified Franz's diffusion cells and human stratum corneum and epidermis (SCE) as a membrane. The permeated and retained amounts of DMSO and alpha-T were determined. The oleogel preparation, the hydrophilic gel and the o/w emulsion were uniform in colour and aspect, without any evidences of phase separation over the period of the study. Hydrophilic ointments were discarded as they showed phase separation after 12 h. All formulations had a different behaviour in terms of skin permeability. In particular, hydrogel and o/w emulsion showed the best control on the drug release considering the interactions of the vehicle components with the SCE and the drugs partition between the vehicle and the SCE. The DMSO permeated amount after 24 h was 4.1 mg/cm(2) for hydrogel and 2.5 mg/cm(2) for emulsion while the permeated amount of pure DMSO after 24 h was 47.5 mg/cm(2). Therefore, aiming to reduce side effects after the topical application of the antidotes DMSO and alpha-T, these results suggested that hydrogel and o/w emulsion could be considered the most promising formulations for further clinical evaluations in managing of extravasation of anthracyclines.</description><identifier>ISSN: 0340-3696</identifier><identifier>EISSN: 1432-069X</identifier><identifier>DOI: 10.1007/s00403-007-0746-9</identifier><identifier>PMID: 17370081</identifier><identifier>CODEN: ADREDL</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Administration, Topical ; alpha-Tocopherol - administration &amp; dosage ; alpha-Tocopherol - adverse effects ; alpha-Tocopherol - therapeutic use ; Anthracycline ; Anthracyclines - metabolism ; Antidotes ; Antioxidants - administration &amp; dosage ; Antioxidants - therapeutic use ; Biological and medical sciences ; Chemotherapy ; Dermatology ; Dimethyl sulfoxide ; Dimethyl Sulfoxide - administration &amp; dosage ; Dimethyl Sulfoxide - adverse effects ; Dimethyl Sulfoxide - therapeutic use ; Disease prevention ; Emulsions ; Epidermis ; Extravasation ; Extravasation of Diagnostic and Therapeutic Materials - drug therapy ; Female ; Humans ; Hydrogels ; Lipophilic ; Medical sciences ; Ointments ; Patients ; Permeability ; Side effects ; Skin ; Skin - drug effects ; Skin - metabolism ; Skin Ulcer - prevention &amp; control ; Stratum corneum ; Topical application ; Topical medication ; Ulcers ; Vitamin E ; Wound healing</subject><ispartof>Archives of Dermatological Research, 2007-07, Vol.299 (4), p.201-207</ispartof><rights>2007 INIST-CNRS</rights><rights>Springer-Verlag 2007.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-c1a6e16d1825c241890fc63623fb9d1a8724b2eb0a58291f2f4bd35a011d49613</citedby><cites>FETCH-LOGICAL-c357t-c1a6e16d1825c241890fc63623fb9d1a8724b2eb0a58291f2f4bd35a011d49613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18883106$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17370081$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CASIRAGHI, Antonella</creatorcontrib><creatorcontrib>ARDOVINO, Paola</creatorcontrib><creatorcontrib>MINGHETTI, Paola</creatorcontrib><creatorcontrib>BOTTA, Cinzia</creatorcontrib><creatorcontrib>GATTINI, Arrigo</creatorcontrib><creatorcontrib>MONTANARI, Luisa</creatorcontrib><title>Semisolid formulations containing dimethyl sulfoxide and α-tocopherol for the treatment of extravasation of antiblastic agents</title><title>Archives of Dermatological Research</title><addtitle>Arch Dermatol Res</addtitle><description>The topical treatment with dimethyl sulfoxide (DMSO) and/or alpha-tocopherol (alpha-T) is widely used in order to prevent the local complications of extravasation of cytostatic drugs and protect patients against skin ulceration. Till now, DMSO and alpha-T have been mainly used in solution. The goal of this study was to formulate semisolid preparations for cutaneous application differing in the hydrophilic and lipophilic properties and containing DMSO and alpha-T in combination. With respect to solutions, the use of semisolid preparations containing DMSO and alpha-T could be advantageous in patients having extravasation as DMSO and alpha-T can remain in contact with the skin over an extended period of time. As a consequence, the action of the active principles can be limited specifically on the injured skin area, reducing the cutaneous irritative effects of DMSO. The following types of semisolid formulations containing 50% m/m DMSO and 2.5% m/m alpha-T were prepared: hydrophilic ointment, o/w emulsion, hydrophilic gel and lipophilic gel. The ex vivo skin permeation of DMSO and alpha-T was evaluated by using modified Franz's diffusion cells and human stratum corneum and epidermis (SCE) as a membrane. The permeated and retained amounts of DMSO and alpha-T were determined. The oleogel preparation, the hydrophilic gel and the o/w emulsion were uniform in colour and aspect, without any evidences of phase separation over the period of the study. Hydrophilic ointments were discarded as they showed phase separation after 12 h. All formulations had a different behaviour in terms of skin permeability. In particular, hydrogel and o/w emulsion showed the best control on the drug release considering the interactions of the vehicle components with the SCE and the drugs partition between the vehicle and the SCE. The DMSO permeated amount after 24 h was 4.1 mg/cm(2) for hydrogel and 2.5 mg/cm(2) for emulsion while the permeated amount of pure DMSO after 24 h was 47.5 mg/cm(2). Therefore, aiming to reduce side effects after the topical application of the antidotes DMSO and alpha-T, these results suggested that hydrogel and o/w emulsion could be considered the most promising formulations for further clinical evaluations in managing of extravasation of anthracyclines.</description><subject>Administration, Topical</subject><subject>alpha-Tocopherol - administration &amp; dosage</subject><subject>alpha-Tocopherol - adverse effects</subject><subject>alpha-Tocopherol - therapeutic use</subject><subject>Anthracycline</subject><subject>Anthracyclines - metabolism</subject><subject>Antidotes</subject><subject>Antioxidants - administration &amp; dosage</subject><subject>Antioxidants - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Dermatology</subject><subject>Dimethyl sulfoxide</subject><subject>Dimethyl Sulfoxide - administration &amp; dosage</subject><subject>Dimethyl Sulfoxide - adverse effects</subject><subject>Dimethyl Sulfoxide - therapeutic use</subject><subject>Disease prevention</subject><subject>Emulsions</subject><subject>Epidermis</subject><subject>Extravasation</subject><subject>Extravasation of Diagnostic and Therapeutic Materials - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrogels</subject><subject>Lipophilic</subject><subject>Medical sciences</subject><subject>Ointments</subject><subject>Patients</subject><subject>Permeability</subject><subject>Side effects</subject><subject>Skin</subject><subject>Skin - drug effects</subject><subject>Skin - metabolism</subject><subject>Skin Ulcer - prevention &amp; control</subject><subject>Stratum corneum</subject><subject>Topical application</subject><subject>Topical medication</subject><subject>Ulcers</subject><subject>Vitamin E</subject><subject>Wound healing</subject><issn>0340-3696</issn><issn>1432-069X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1qHDEQhUWIiQfbB8gmCEKWcko_I6mXwcRJwJBFHMiuUevHI9MtTSR1sFc5Uy7iM6XbM-Da1KP43it4CL2lcEkB1McKIICTRRJQQpLuFdpQwRkB2f16jTbABRAuO3mKLmq9h2UUCAbqDTqliisATTfo7w8_xZrH6HDIZZpH02JOFducmokppjvs4uTb7nHEdR5DfojOY5McfvpHWrZ5v_Mlj6sZt53HrXjTJp8azgH7h1bMH1OfM9eDSS0Oo6ktWmzuFqqeo5NgxuovjvsM_bz-fHv1ldx8__Lt6tMNsXyrGrHUSE-lo5ptLRNUdxCs5JLxMHSOGq2YGJgfwGw162hgQQyObw1Q6kQnKT9D7w-5-5J_z762_j7PJS0veyal0FItmQtFD5QtudbiQ78vcTLlsafQr633h9b7Va6t96vn3TF5HibvXhzHjhfgwxEw1ZoxFJNsrC-c1ppTkPw_kdiMxg</recordid><startdate>20070701</startdate><enddate>20070701</enddate><creator>CASIRAGHI, Antonella</creator><creator>ARDOVINO, Paola</creator><creator>MINGHETTI, Paola</creator><creator>BOTTA, Cinzia</creator><creator>GATTINI, Arrigo</creator><creator>MONTANARI, Luisa</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope></search><sort><creationdate>20070701</creationdate><title>Semisolid formulations containing dimethyl sulfoxide and α-tocopherol for the treatment of extravasation of antiblastic agents</title><author>CASIRAGHI, Antonella ; ARDOVINO, Paola ; MINGHETTI, Paola ; BOTTA, Cinzia ; GATTINI, Arrigo ; MONTANARI, Luisa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-c1a6e16d1825c241890fc63623fb9d1a8724b2eb0a58291f2f4bd35a011d49613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Administration, Topical</topic><topic>alpha-Tocopherol - administration &amp; dosage</topic><topic>alpha-Tocopherol - adverse effects</topic><topic>alpha-Tocopherol - therapeutic use</topic><topic>Anthracycline</topic><topic>Anthracyclines - metabolism</topic><topic>Antidotes</topic><topic>Antioxidants - administration &amp; dosage</topic><topic>Antioxidants - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Dermatology</topic><topic>Dimethyl sulfoxide</topic><topic>Dimethyl Sulfoxide - administration &amp; dosage</topic><topic>Dimethyl Sulfoxide - adverse effects</topic><topic>Dimethyl Sulfoxide - therapeutic use</topic><topic>Disease prevention</topic><topic>Emulsions</topic><topic>Epidermis</topic><topic>Extravasation</topic><topic>Extravasation of Diagnostic and Therapeutic Materials - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrogels</topic><topic>Lipophilic</topic><topic>Medical sciences</topic><topic>Ointments</topic><topic>Patients</topic><topic>Permeability</topic><topic>Side effects</topic><topic>Skin</topic><topic>Skin - drug effects</topic><topic>Skin - metabolism</topic><topic>Skin Ulcer - prevention &amp; control</topic><topic>Stratum corneum</topic><topic>Topical application</topic><topic>Topical medication</topic><topic>Ulcers</topic><topic>Vitamin E</topic><topic>Wound healing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CASIRAGHI, Antonella</creatorcontrib><creatorcontrib>ARDOVINO, Paola</creatorcontrib><creatorcontrib>MINGHETTI, Paola</creatorcontrib><creatorcontrib>BOTTA, Cinzia</creatorcontrib><creatorcontrib>GATTINI, Arrigo</creatorcontrib><creatorcontrib>MONTANARI, Luisa</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>Archives of Dermatological Research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CASIRAGHI, Antonella</au><au>ARDOVINO, Paola</au><au>MINGHETTI, Paola</au><au>BOTTA, Cinzia</au><au>GATTINI, Arrigo</au><au>MONTANARI, Luisa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Semisolid formulations containing dimethyl sulfoxide and α-tocopherol for the treatment of extravasation of antiblastic agents</atitle><jtitle>Archives of Dermatological Research</jtitle><addtitle>Arch Dermatol Res</addtitle><date>2007-07-01</date><risdate>2007</risdate><volume>299</volume><issue>4</issue><spage>201</spage><epage>207</epage><pages>201-207</pages><issn>0340-3696</issn><eissn>1432-069X</eissn><coden>ADREDL</coden><abstract>The topical treatment with dimethyl sulfoxide (DMSO) and/or alpha-tocopherol (alpha-T) is widely used in order to prevent the local complications of extravasation of cytostatic drugs and protect patients against skin ulceration. Till now, DMSO and alpha-T have been mainly used in solution. The goal of this study was to formulate semisolid preparations for cutaneous application differing in the hydrophilic and lipophilic properties and containing DMSO and alpha-T in combination. With respect to solutions, the use of semisolid preparations containing DMSO and alpha-T could be advantageous in patients having extravasation as DMSO and alpha-T can remain in contact with the skin over an extended period of time. As a consequence, the action of the active principles can be limited specifically on the injured skin area, reducing the cutaneous irritative effects of DMSO. The following types of semisolid formulations containing 50% m/m DMSO and 2.5% m/m alpha-T were prepared: hydrophilic ointment, o/w emulsion, hydrophilic gel and lipophilic gel. The ex vivo skin permeation of DMSO and alpha-T was evaluated by using modified Franz's diffusion cells and human stratum corneum and epidermis (SCE) as a membrane. The permeated and retained amounts of DMSO and alpha-T were determined. The oleogel preparation, the hydrophilic gel and the o/w emulsion were uniform in colour and aspect, without any evidences of phase separation over the period of the study. Hydrophilic ointments were discarded as they showed phase separation after 12 h. All formulations had a different behaviour in terms of skin permeability. In particular, hydrogel and o/w emulsion showed the best control on the drug release considering the interactions of the vehicle components with the SCE and the drugs partition between the vehicle and the SCE. The DMSO permeated amount after 24 h was 4.1 mg/cm(2) for hydrogel and 2.5 mg/cm(2) for emulsion while the permeated amount of pure DMSO after 24 h was 47.5 mg/cm(2). Therefore, aiming to reduce side effects after the topical application of the antidotes DMSO and alpha-T, these results suggested that hydrogel and o/w emulsion could be considered the most promising formulations for further clinical evaluations in managing of extravasation of anthracyclines.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>17370081</pmid><doi>10.1007/s00403-007-0746-9</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0340-3696
ispartof Archives of Dermatological Research, 2007-07, Vol.299 (4), p.201-207
issn 0340-3696
1432-069X
language eng
recordid cdi_proquest_journals_2664867189
source MEDLINE; SpringerNature Complete Journals
subjects Administration, Topical
alpha-Tocopherol - administration & dosage
alpha-Tocopherol - adverse effects
alpha-Tocopherol - therapeutic use
Anthracycline
Anthracyclines - metabolism
Antidotes
Antioxidants - administration & dosage
Antioxidants - therapeutic use
Biological and medical sciences
Chemotherapy
Dermatology
Dimethyl sulfoxide
Dimethyl Sulfoxide - administration & dosage
Dimethyl Sulfoxide - adverse effects
Dimethyl Sulfoxide - therapeutic use
Disease prevention
Emulsions
Epidermis
Extravasation
Extravasation of Diagnostic and Therapeutic Materials - drug therapy
Female
Humans
Hydrogels
Lipophilic
Medical sciences
Ointments
Patients
Permeability
Side effects
Skin
Skin - drug effects
Skin - metabolism
Skin Ulcer - prevention & control
Stratum corneum
Topical application
Topical medication
Ulcers
Vitamin E
Wound healing
title Semisolid formulations containing dimethyl sulfoxide and α-tocopherol for the treatment of extravasation of antiblastic agents
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T06%3A29%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Semisolid%20formulations%20containing%20dimethyl%20sulfoxide%20and%20%CE%B1-tocopherol%20for%20the%20treatment%20of%20extravasation%20of%20antiblastic%20agents&rft.jtitle=Archives%20of%20Dermatological%20Research&rft.au=CASIRAGHI,%20Antonella&rft.date=2007-07-01&rft.volume=299&rft.issue=4&rft.spage=201&rft.epage=207&rft.pages=201-207&rft.issn=0340-3696&rft.eissn=1432-069X&rft.coden=ADREDL&rft_id=info:doi/10.1007/s00403-007-0746-9&rft_dat=%3Cproquest_cross%3E2664867189%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2664867189&rft_id=info:pmid/17370081&rfr_iscdi=true